SunWay Biotech Co., LTD.
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. The company also researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus… Read more
SunWay Biotech Co., LTD. (1271) - Total Liabilities
Latest total liabilities as of June 2025: NT$939.36 Million TWD
Based on the latest financial reports, SunWay Biotech Co., LTD. (1271) has total liabilities worth NT$939.36 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SunWay Biotech Co., LTD. - Total Liabilities Trend (2019–2024)
This chart illustrates how SunWay Biotech Co., LTD.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SunWay Biotech Co., LTD. Competitors by Total Liabilities
The table below lists competitors of SunWay Biotech Co., LTD. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suyog Telematics Limited
NSE:SUYOG
|
India | ₹3.37 Billion |
|
Afya Limited
SA:A2FY34
|
Brazil | R$4.44 Billion |
|
Mitake Information
TWO:8284
|
Taiwan | NT$849.50 Million |
|
Sinew Pharma Inc.
TWO:6634
|
Taiwan | NT$35.10 Million |
|
China Automotive Systems Inc
NASDAQ:CAAS
|
USA | $513.31 Million |
|
Horizon Space Acquisition II Corp. Units
NASDAQ:HSPTU
|
USA | $558.75K |
|
Softronic AB
ST:SOF-B
|
Sweden | Skr167.70 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down SunWay Biotech Co., LTD.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SunWay Biotech Co., LTD.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SunWay Biotech Co., LTD. (2019–2024)
The table below shows the annual total liabilities of SunWay Biotech Co., LTD. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$527.13 Million | +15.82% |
| 2023-12-31 | NT$455.11 Million | +139.35% |
| 2022-12-31 | NT$190.14 Million | +213.51% |
| 2021-12-31 | NT$60.65 Million | +30.34% |
| 2020-12-31 | NT$46.53 Million | +20.61% |
| 2019-12-31 | NT$38.58 Million | -- |